John F R Robertson
Overview
Explore the profile of John F R Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robertson J, Shao Z, Noguchi S, Bondarenko I, Panasci L, Singh S, et al.
J Clin Oncol
. 2025 Feb;
43(8):1045.
PMID: 39919260
No abstract available.
2.
Robertson J, Shao Z, Noguchi S, Bondarenko I, Panasci L, Singh S, et al.
J Clin Oncol
. 2025 Jan;
:JCO2400994.
PMID: 39772884
The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative...
3.
Jin X, Zhou Y, Ma D, Zhao S, Lin C, Xiao Y, et al.
Nat Genet
. 2023 Sep;
55(10):1696-1708.
PMID: 37770634
Hormone receptor-positive (HR)/human epidermal growth factor receptor 2-negative (HER2) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges....
4.
Bliss J, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al.
Breast Cancer Res
. 2023 Apr;
25(1):39.
PMID: 37046348
Purpose: Ki67 assessed at diagnosis (Ki67) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki67) is associated with...
5.
Robertson J, Coleman R, Cheung K, Evans A, Holcombe C, Skene A, et al.
Clin Cancer Res
. 2022 Dec;
28(24):5469.
PMID: 36519303
No abstract available.
6.
Bergamino M, Morani G, Parker J, Schuster E, Leal M, Lopez-Knowles E, et al.
Clin Cancer Res
. 2021 Dec;
28(6):1217-1228.
PMID: 34965950
Purpose: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular...
7.
Robertson J, Sewell H
Lancet
. 2021 Jun;
397(10291):2248-2249.
PMID: 34119060
No abstract available.
8.
Agius R, Hughes L, Kendrick D, Robertson J, Stewart M
BMJ
. 2021 Apr;
373:n950.
PMID: 33849911
No abstract available.
9.
Robertson J, Sewell H, Stewart M
Lancet
. 2021 Feb;
397(10277):879-880.
PMID: 33617766
No abstract available.
10.
Robertson J, Di Leo A, Johnston S, Chia S, Bliss J, Paridaens R, et al.
NPJ Breast Cancer
. 2021 Feb;
7(1):11.
PMID: 33579962
Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of...